Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. Bonny C, et al. Among authors: marcellin p. Aliment Pharmacol Ther. 2006 Aug 15;24(4):593-600. doi: 10.1111/j.1365-2036.2006.03018.x. Aliment Pharmacol Ther. 2006. PMID: 16907892 Free article.
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group. Poynard T, et al. Among authors: marcellin p. J Viral Hepat. 2003 May;10(3):197-204. doi: 10.1046/j.1365-2893.2003.00427.x. J Viral Hepat. 2003. PMID: 12753338 Clinical Trial.
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F; Observational VHC4 Study Group. Roulot D, et al. Among authors: marcellin p. J Viral Hepat. 2007 Jul;14(7):460-7. doi: 10.1111/j.1365-2893.2006.00823.x. J Viral Hepat. 2007. PMID: 17576387
The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.
Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, Capeau J, Carrieri P, Larrey D, Larsen C, Marcellin P, Pawlostky JM, Nahon P, Zoulim F, Cacoub P, de Ledinghen V, Mathurin P, Negro F, Pageaux GP, Yazdanpanah Y, Wittkop L, Zarski JP, Carrat F; French Anrs Co22 Hepather Cohort. Pol S, et al. Among authors: marcellin p. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1054-1060. doi: 10.1111/apt.14352. Epub 2017 Oct 9. Aliment Pharmacol Ther. 2017. PMID: 28994127
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Payan C, et al. Among authors: marcellin p. J Viral Hepat. 2005 Jul;12(4):405-13. doi: 10.1111/j.1365-2893.2005.00605.x. J Viral Hepat. 2005. PMID: 15985012
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Poynard T, et al. Among authors: marcellin p. Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4. Lancet. 1998. PMID: 9807989 Clinical Trial.
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y; Adefovir Dipivoxil 437 and 438 Study Groups. Poynard T, et al. Among authors: marcellin p. J Viral Hepat. 2009 Mar;16(3):203-13. doi: 10.1111/j.1365-2893.2008.01065.x. Epub 2008 Oct 22. J Viral Hepat. 2009. PMID: 19175871 Clinical Trial.
Boceprevir for untreated chronic HCV genotype 1 infection.
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Poordad F, et al. N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494. N Engl J Med. 2011. PMID: 21449783 Free PMC article. Clinical Trial.
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators. Sulkowski MS, et al. Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11. Hepatology. 2013. PMID: 23081753 Clinical Trial.
558 results